Skip to search boxSkip to navigationSkip to main content

Intracellular reduction in ATP levels contributes to CYT997-induced suppression of metastasis of head and neck squamous carcinoma

  • Xiangdong Zhao
    ,
  • Liwei Lang
    ,
  • Leilei He
    ,
  • Lixia Gao
    ,
  • David Chyan
    ,
  • Yuanping Xiong
*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Abstract

The incidence rate of head and neck squamous cell carcinoma (HNSCC) has steadily increased over the past decade. However, treatment options for metastatic HNSCC are often limited and the 5-year survival rate has remained static. Therefore, the development and assessment of more efficient but less toxic therapeutic strategies is an unmet need for treatment of more extensive HNSCC. Here, we report that CYT997, a novel microtubule-disrupting agent, exerts strong activity in inhibiting HNSCC cell invasion and metastasis. The loss of invasion capacity by CYT997 was accompanied by an associated increase in cell adhesion and the reversal of epithelial-mesenchymal transition (EMT). Increased expression of E-cadherin protein and decreased expression of Vimentin protein became evident in HNSCC cells following CYT997 exposure, which were consistently observed in HNSCC xenografts from the mice receiving CYT997. Moreover, the capacity of invasive HNSCC cells to form pulmonary metastases was significantly blocked with CYT997 treatment, indicating that the diminishment of EMT traits contributes to CYT997-suppressed metastasis. Intriguingly, CYT997 impaired intracellular ATP levels in HNSCC cells, at least in part, through its inhibitory effect on the mitochondrial protein IF1. The addition of ATP attenuated CYT997-induced suppression of cell invasion, coupled with down-regulation of E-Cadherin and up-regulation of Vimentin. These findings support a critical role of ATP levels in cell invasion and metastasis under the influence of CYT997. Collectively, our data unveil the mechanism involved in mediating CYT997 action, and provide preclinical rationale for possible clinical application of CYT997 as a novel therapeutic strategy against aggressive HNSCC.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 1174-1182 (9 pages)

Journal (Volume, Issue Number)

Journal of Cellular and Molecular Medicine (Volume 23, Issue 2)

Publication milestones

  • Accepted/In press - 01/01/2018
  • Published - 02/2019

Publication status

Published - 02/2019

ISSN

1582-1838

Publication IDs

  • Scopus: 85056782279
  • PubMed: 30450674
  • ORCID: /0000-0002-1856-7289/work/62481080

Publication metrics

Metrics

Fractional count
2
Fractional count
0.22
Fractional count
7
Fractional count
0.78
Fractional count
2
Fractional count
1
Scopus
citations
SciVal
FWCI
0.26
SciVal
Author count
9
SciVal
citations
2
SciVal
Paper percentile
58

PlumX, opens in new tab

Captures
16
Citation count
6

Funding Details

This work was supported in part by Augusta University Faculty Startup Fund.
FunderFunding numbersAugusta University-